相关临床试验
110
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
进行中（未招募）
4
3.6%
已完成
36
32.7%
Enrolling By Invitation
2
1.8%
No Longer Available
1
0.9%
尚未招募
4
3.6%
招募中
21
19.1%
暂停
3
2.7%
终止
27
24.6%
Unknown
1
0.9%
撤回
11
10.0%
暂无批准数据
- BioVersys has entered an exclusive collaboration and license agreement with Hackensack Meridian Health to jointly develop ansamycin antimicrobial candidates targeting difficult-to-treat non-tuberculous mycobacteria (NTM) infections. - The partnership combines BioVersys' proprietary Ansamycin Chemistry platform with advanced lead molecules from HMH's Center for Discovery and Innovation, strengthening the pool of orally bioavailable anti-NTM candidates. - NTM pulmonary disease affects approximately 250,000 people annually with current cure rates as low as 30-50%, representing a significant unmet medical need for vulnerable populations including cystic fibrosis patients. - The collaboration aims to address the growing crisis of NTM infections, which have increased from 3.3% to 22.6% among cystic fibrosis patients, with some pathogens associated with up to 50% mortality rates.
- SpotitEarly has formed a strategic partnership with Fox Chase Cancer Center to conduct multi-year clinical trials evaluating its breath-based cancer detection test in lung cancer patients. - The collaboration combines SpotitEarly's proprietary LUCID bio-AI hybrid platform, which uses trained canines and artificial intelligence to identify cancer odor signatures in breath samples. - Previous clinical studies involving over 1,300 participants demonstrated the platform's overall sensitivity of approximately 94% across four common cancers with strong early-stage performance. - This partnership follows SpotitEarly's recent collaboration with Hackensack Meridian Health, highlighting growing confidence in the company's innovative approach to early cancer detection.
- The FDA has accepted Compass Pathways' Investigational New Drug application for COMP360, enabling initiation of a Phase 2b/3 clinical trial in patients with post-traumatic stress disorder. - The multicenter study will evaluate two 25 mg doses of COMP360 versus 1 mg control doses, with the primary endpoint measuring CAPS-5 total severity score changes at week 8. - Previous Phase 2 data showed COMP360 demonstrated 9.9 and 29.5 point reductions in CAPS-5 scores at weeks 4 and 12, respectively, with no treatment-emergent serious adverse events. - COMP360 represents a potential first-in-class synthetic psilocybin treatment that has already received breakthrough therapy designation for treatment-resistant depression.
- Hackensack Meridian Health opened a new cancer center at JFK University Medical Center in Edison, NJ in May 2025, bringing together multiple oncology specialties under one roof. - The facility's design promotes real-time collaboration among medical oncologists, surgeons, radiation oncologists, and support services, enabling faster clinical decision-making for cancer patients. - Leadership emphasizes that strong network infrastructure and centralized resources, including financial counseling and insurance navigation, help reduce physician burnout while improving patient care.
- RWJBarnabas Health and Rutgers Cancer Institute have opened the Jack & Sheryl Morris Cancer Center in New Brunswick, marking New Jersey's first freestanding comprehensive cancer hospital. - The 12-story facility features 96 inpatient beds, 88 infusion bays, dedicated surgical floors, and research infrastructure, eliminating the need for New Jersey residents to travel to New York or Philadelphia for specialized cancer treatment. - Hackensack Meridian Health has also expanded its John Theurer Cancer Center in Edison with a $14 million renovation, doubling infusion capacity and enhancing surgical, medical, and radiation oncology services.
• Cancer vaccines are gaining momentum across multiple tumor types, with FDA-approved options like BCG, sipuleucel-T, and talimogene laherparepvec demonstrating clinical utility in bladder cancer, prostate cancer, and melanoma respectively. • Novel vaccine approaches including mRNA-based mRNA-4157, KRAS-targeted ELI-002, and viral vector-based aglatimagene besadenovec are showing promising results in clinical trials, with significant improvements in survival outcomes across various cancers. • Experts believe cancer vaccines hold particular promise in early-stage and high-risk disease settings by targeting micrometastatic disease, potentially increasing cure rates and transforming treatment paradigms when combined with existing immunotherapies.
- A phase 1 dose-escalation trial evaluating PIPAC-MMC combined with systemic chemotherapy demonstrated manageable safety profile in patients with appendiceal and colorectal peritoneal metastases. - The minimally invasive laparoscopic approach delivers aerosolized mitomycin C directly to peritoneal tumors every 6 weeks, addressing the historical challenge of poor drug penetration to these sites. - Safety results showed 58% of patients experienced grade 1-2 toxicities as the highest grade, while 31% experienced grade 3 or higher toxicities across dose levels. - PIPAC represents a significant advancement over traditional approaches like cytoreductive surgery with HIPEC, offering shorter procedures and same-day discharge for patients with peritoneal carcinomatosis.
